Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $95.34 USD
Change Today -1.34 / -1.39%
Volume 1.4M
SYK On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

stryker corp (SYK) Snapshot

Open
$95.71
Previous Close
$96.68
Day High
$96.26
Day Low
$94.52
52 Week High
08/19/15 - $105.34
52 Week Low
10/15/14 - $77.87
Market Cap
35.9B
Average Volume 10 Days
2.1M
EPS TTM
$4.50
Shares Outstanding
376.6M
EX-Date
09/28/15
P/E TM
21.2x
Dividend
$1.38
Dividend Yield
1.41%
Current Stock Chart for STRYKER CORP (SYK)

stryker corp (SYK) Details

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment offers implants used in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment provides surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, and reprocessed and remanufactured medical devices, as well as other medical device products for use in various medical specialties. The Neurotechnology and Spine segment offers neurosurgical and neurovascular devices that include products used for minimally invasive endovascular techniques; products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also develops, manufactures, and markets spinal implant products, including cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company markets its products to doctors, hospitals, and other healthcare facilities in the United States; and sells its products through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 100 countries internationally. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

26,000 Employees
Last Reported Date: 02/12/15
Founded in 1941

stryker corp (SYK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President
Total Annual Compensation: $536.7K
Group President of Medsurg & Neurotechnology
Total Annual Compensation: $568.5K
Group President of International
Total Annual Compensation: $526.7K
Group President of Orthopaedics
Total Annual Compensation: $513.3K
Compensation as of Fiscal Year 2014.

stryker corp (SYK) Key Developments

Stryker Corporation Receives Food and Drug Administration Clearance for Mako Total Knee Application

Stryker Corporation announced that its 510(k) submission for the Mako total knee application has received market clearance by the U.S. Food and Drug Administration. This clearance expands Stryker's current Mako offering of partial knee and total hip applications to provide a comprehensive solution in the robotic reconstructive service line. With the clearance of the total knee application, Stryker is preparing to initiate a limited market release by year end.

Stryker Corporation Declares Quarterly Dividend, Payable on October 30, 2015

Stryker Corporation announced that its Board of Directors has declared a quarterly dividend of $0.345 per share payable on October 30, 2015, to shareholders of record at the close of business on September 30, 2015, representing an increase of 13% versus the prior year, and unchanged from the previous quarter.

Stryker Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal 2015

Stryker announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported second quarter net income of $392 million or $1.03 per diluted share, compared with the prior-year period's $128 million or $0.33 per diluted share. Adjusted net income was $458 million or $1.20 per share, ex one-time items, versus $415 million or $1.08 in the same quarter the previous year. Revenue was $2.43 billion, up 2.9% from $2.36 billion in the same quarter last year, net sales were negatively impacted by 4.7% due to the impact of foreign currency exchange rates. Excluding the 0.7% impact of acquisitions, net sales in the quarter increased 6.9% in constant currency, including 8.7% from increased unit volume partially offset by 1.8% lower prices. Operating income was $429 million against $197 million a year ago. Earnings before income taxes were $401 million against $167 million a year ago. Adjusted operating income was $579 million against $565 million a year ago. For the six months, the company reported net sales were $4,811 million against $4,668 million a year ago. Operating income was $835 million against $328 million a year ago. Earnings before income taxes were $778 million against $274 million a year ago. Net earnings were $616 million against $198 million a year ago. Diluted earnings per share were $1.61 against $0.51 a year ago. Net cash provided by operating activities was $737 million against $579 million a year ago. Purchases of property, plant and equipment was $114 million against $124 million a year ago. Adjusted operating income was $1,134 million against $1,121 million a year ago. Adjusted net earnings were $882 million against $819 million a year ago. Adjusted diluted earnings per share were $2.31 against $2.14 a year ago. For the third quarter of 2015, the company sees adjusted EPS of $1.20 - $1.25. The company expects fiscal 2015 adjusted EPS of $5.06 - $5.12. It sees constant currency sales growth in the range of 6.5% to 7.5% for the year, including organic sales growth in the range of 5.5% to 6.5%. The company also expects expect sales in the third quarter and fiscal 2015 to be negatively impacted by 3.5% to 4.0% and adjusted diluted net earnings per share to be negatively impacted by approximately $0.25 in the full year. Capital expenditures are expected to run higher than last year as move through 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYK:US $95.34 USD -1.34

SYK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $134.32 USD -2.21
Boston Scientific Corp $16.24 USD -0.29
Ecolab Inc $106.54 USD -2.29
Kimberly-Clark Corp $103.52 USD -2.12
Zimmer Biomet Holdings Inc $100.46 USD -1.63
View Industry Companies
 

Industry Analysis

SYK

Industry Average

Valuation SYK Industry Range
Price/Earnings 39.6x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 32.3x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRYKER CORP, please visit www.strykercorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.